Epidemiology and risk factors for infection in multiple myeloma patients treated with bispecific antibodies
Clicks: 2
ID: 324804
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
2 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #109 of 208 articles by views in Open forum infectious diseases
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 208 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Background Bispecific antibodies (BsAbs) have revolutionized multiple myeloma (MM) treatment but are associated with infectious complications. This study aims to characterize the incidence, microbiological patterns, and risk factors for infection in this population. Methods We conducted an observational cohort study of adult MM patients treated with BsAbs at a single center between 2020 and 2025. Clinical and microbiological features of different types of infection were analyzed. Risk factors for recurrent events were assessed by Cox regression. Results Among 92 patients receiving 98 BsAbs courses, 352 infectious episodes were identified (incidence rate: 3.20 episodes per BsAbs course-year). Most common syndromes were respiratory (71.3%) and digestive (11.9%), with predominant viral etiology (62.8%). Severe (grade ≥3) infections occurred in 45.9% of courses. Anti-BCMA BsAbs carried a higher infection risk than anti-GPRC5D therapy (aHR: 1.41, 95% CI: 1.02-1.94; P-value = 0.035). Previous BsAb exposure (aHR: 1.75, 95% CI: 1.23-2.50; P-value = 0.002), allogeneic hematopoietic stem-cell transplantation (aHR: 1.59, 95% CI: 1.12-2.26; P-value = 0.010), and development of immune effector cell-associated neurotoxicity syndrome (ICANS) (aHR: 3.23, 95% CI: 1.27–8.19; P-value = 0.001) increased the risk of infection. Intravenous immunoglobulin (IVIg) therapy was protective (aHR: 0.68, 95% CI: 0.53-0.86; P-value = 0.002). Concurrent infections were documented in only 6.8% of first episodes of cytokine release syndrome (CRS). Conclusion BsAbs therapy for MM is associated with a high infection burden, predominantly respiratory and gastrointestinal. Risk is driven by cumulative immunosuppression and therapy for ICANS, while IVIg therapy reduces this susceptibility. Infections are uncommon during CRS episodes.
| Reference Key |
openalex_W7202256191
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Eduardo Aparicio‐Minguijón, Nieves López‐Muñoz, Guillermo Bartolomé Herguedas, Adolfo Jesús Sáez Marín, María Asunción Pérez‐Jacoiste Asín, José María Sánchez‐Pina, María Calbacho, Jorge Boán, Francisco López‐Medrano, Rafael San Juan, José Tiago Silva, Joaquín Martínez‐López, José María Aguado, Mario Fernández‐Ruiz, Isabel Rodríguez‐Góncer |
| Journal | Open forum infectious diseases |
| Year | 2026 |
| DOI |
10.1093/ofid/ofag505
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.